BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR ...
The company anticipates completing the expansion cohort for preeclampsia in the first half of 2026 and expects the interim analysis of the ReMEDy2 stroke trial based on the first 200 patients in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results